A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure

J Hepatol. 2018 Jun;68(6):1313-1315. doi: 10.1016/j.jhep.2018.03.010. Epub 2018 Apr 3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage*
  • Cohort Studies
  • Drug Resistance, Multiple, Viral
  • Drug Therapy, Combination
  • Egypt
  • Female
  • Hepacivirus / classification
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Imidazoles / administration & dosage
  • Male
  • Middle Aged
  • Ribavirin / administration & dosage
  • Simeprevir / administration & dosage
  • Sofosbuvir / administration & dosage*
  • Sustained Virologic Response
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Imidazoles
  • Ribavirin
  • Simeprevir
  • daclatasvir
  • Sofosbuvir